<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H22C32D389EE049DC8679CBDD1ADB94EA" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>117 HR 8774 IH: Menopause Research Act of 2022</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2022-09-06</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">117th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 8774</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20220906">September 6, 2022</action-date><action-desc><sponsor name-id="M001180">Mr. McKinley</sponsor> (for himself and <cosponsor name-id="A000378">Mrs. Axne</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To require the Director of the National Institutes of Health to conduct an evaluation of menopause-related research (including gaps in research and knowledge regarding the causes, symptoms, and treatments for menopause), to develop a strategic plan to resolve gaps in knowledge and research, and identify topics in need of further research relating to potential treatments for menopause-related symptoms, and for other purposes.</official-title></form><legis-body id="HD85F2CD2FF1E4A20BB3A9214A0162DFF" style="OLC"> 
<section id="H81EF26A4BC3D48F784AD819682761C8C" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Menopause Research Act of 2022</short-title></quote>.</text></section> <section id="H71F63CBC52D0489D811B293907C221F5"><enum>2.</enum><header>Evaluation of menopause-related research</header> <subsection id="HC35D894C872C4BEA993924F6D7AD782F"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">The Director of the National Institutes of Health shall—</text> 
<paragraph id="HF5436F154694479C86C0478EE40D5250"><enum>(1)</enum><text>conduct an evaluation of—</text> <subparagraph id="H35F0920535D340AD945CD6BEAE922AD0"><enum>(A)</enum><text display-inline="yes-display-inline">the results of completed menopause-related research, and research on mid-life women’s health;</text></subparagraph> 
<subparagraph id="H159A22AC20AB4F7FBF129ABE7DDDDC8A"><enum>(B)</enum><text display-inline="yes-display-inline">the status of ongoing menopause-related research, and research on mid-life women’s health; and</text></subparagraph> <subparagraph id="HE2D11E41922445B9834C0741DCC24327"><enum>(C)</enum><text>any gaps in knowledge and research on—</text> 
<clause id="H806E760EF5E04202AC8F0BD633FD19D3"><enum>(i)</enum><text>treatments for menopause-related symptoms; and</text></clause> <clause id="HE01902457BAB4F7E872BAA3C0BD6BD7D"><enum>(ii)</enum><text display-inline="yes-display-inline">the safety and effectiveness of treatments for menopause-related symptoms; and</text></clause></subparagraph></paragraph> 
<paragraph id="HC0128F7CDC604F7ABCA041929B4ECE6C"><enum>(2)</enum><text display-inline="yes-display-inline">as part of such evaluation, identify the total amount of funding allocated by the National Institutes of Health for the conduct or support of menopause-related research, and research on mid-life women’s health over the preceding 5 fiscal years.</text></paragraph></subsection> <subsection id="HEE4B87765D5D427C95BEC992D370EA97"><enum>(b)</enum><header>Report; strategic plan</header><text>Not later than 180 days after the date of enactment of this Act, the Director of the National Institutes of Health shall submit to the Congress—</text> 
<paragraph id="HF2461FE14381417F8480D083B426A133"><enum>(1)</enum><text>a report on the findings of such evaluation; and</text></paragraph> <paragraph id="HCB44A45E9B794BB7AE764F3539E9364F"><enum>(2)</enum><text display-inline="yes-display-inline">a strategic plan—</text> 
<subparagraph id="H0EC6907912F94C9293C2FCA28F35A8B7"><enum>(A)</enum><text>to resolve the gaps in knowledge and research identified in the report; and</text></subparagraph> <subparagraph id="H73293869109547D9A17AB297C80358CE"><enum>(B)</enum><text>to identify topics in need of further research relating to potential treatments for menopause-related symptoms.</text></subparagraph></paragraph></subsection></section> 
<section id="HF4C84FD5D2EF49C5A02490E74EF05BDF"><enum>3.</enum><header>Menopause-related research, and research on mid-life women’s health</header> 
<subsection id="H8CE2C1B1AD1E4E30BDB195B1ADF5645D"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, shall conduct or support menopause-related research, and research on mid-life women’s health. </text></subsection> <subsection id="H30EE09A74DA242B68821C3834DEDD1FA"><enum>(b)</enum><header>Authorization of appropriations</header><text display-inline="yes-display-inline">There is authorized to be appropriated to carry out this section $100,000,000 for each of fiscal years 2023 and 2024.</text></subsection></section> 
</legis-body></bill>

